开元棋牌电脑 |本期目录/Table of Contents|

[1]余霄.葡萄膜黑色素瘤的治疗现状[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2019,39(4):398-400.[doi:10.13389/j.cnki.rao.2019.0091]
 YU Xiao.Management status of uveal melanoma[J].Recent Advances in Ophthalmology,2019,39(4):398-400.[doi:10.13389/j.cnki.rao.2019.0091]
点击复制

葡萄膜黑色素瘤的治疗现状(/HTML)
分享到:

《开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷》[ISSN:1003-5141/CN:41-1105/R]

卷:
39卷
期数:
2019年4期
页码:
398-400
栏目:
文献综述
出版日期:
2019-04-05

文章信息/Info

Title:
Management status of uveal melanoma
作者:
余霄
匈牙利德布勒森市,德布勒森大学
Author(s):
YU Xiao
University of Debrecen,Debrecen,Hungary
关键词:
葡萄膜黑色素瘤治疗现状
Keywords:
uveal melanomamanagementstatus
分类号:
R773.9
DOI:
10.13389/j.cnki.rao.2019.0091
文献标志码:
A
摘要:
葡萄膜黑色素瘤(uveal melanoma,UM)是起源于葡萄膜黑色素细胞的眼内恶性肿瘤。由于其生存率很大程度上取决于原发肿瘤的大小,因此早发现、早治疗非常重要。目前,UM尚无有效的辅助治疗方法。但分子生物学方面的新发现,如GNAQ和GNA11突变和涉及下游信号传导通路MAPK、PI3K/Akt和Hippo为代表的多种治疗,则有助于对UM发病机制的理解。还有研究开辟了新的生物标志物范围,以提高对UM转移的检测。此外,许多研究和临床试验也正在进行中。
Abstract:
Intra-ocular malignancy such as uveal melanoma (UM) arises from melanocytes from the uveal tract.It is paramount to detect early so as to initiate therapeutic plan as much of the survival will depend of the primary tumor size.Currently,no adjuvant therapy has demonstrated survival benefit and new insights in molecular biology,and has improved our comprehension of the pathogenesis essentially through GNAQ and GNA11 mutations and downstream signaling pathways MAPK,PI3K/Akt and Hippo,representing a multitude of therapeutic application.New research has also unfolded new range of biomarkers that could be exploited in this setting so as to improve metastasis detection.Many studies and clinical trials are ongoing.

参考文献/References:

[1] MAHENDRARAJ K,SHRESTHA S,LAU C S,CHAMBERLAIN R S.Ocular melanoma-when you have seen one,you have not seen them all:A clinical outcome study from the surveillance,epidemiology and end results (SEER) database (1973-2012)[J].Clin Ophthalmol,2017,11:153-160.
[2] AMARO A,GANGEMI R,PIAGGIO F,ANGELINI G,BARISIONE G,FERRINI S,et al.The biology of uveal melanoma[J].Cancer Metastasis Rev,2017,36(1):109-140.
[3] HARBOUR J W.A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile[J].Methods Mol Biol,2014,1102:427- 440.
[4] CHATTOPADHYAY C,KIM D W,GOMBOS D S,OBA J,QIN Y,WILLIAMS M D,et al.Uveal melanoma:from diagnosis to treatment and the science in between cancer[J].Cancer,2016,122(15):2299-2312.
[5] CARVAJAL R D,SCHWARTZ G K,TEZEL T,MARR B,FRANCIS J H,NATHAN P D,Metastatic disease from uveal melanoma:treatment options and prospects[J].Br J Ophthalmol,2017,101(1):38-44.
[6] JOVANOVIC P,MIHAJLOVIC M,DJORDJEVIC-JOCIC J,VLAJKOVIC S,CEKIC S,STEFANOVIC V.Ocular melanoma:An overview of the current status[J].Inter Clin Exper Patholol,2013,15,6(7):1230-1244.
[7] DAMATO B.Does ocular treatment of uveal melanoma influence survival.British[J].Cancer,2010,103(3):285-290.
[8] MAHAJAN A,CRUM A,JOHNSON M H,MATERIN M A.Ocular neoplastic disease[J].Seminars Ultrasound,CT MRI,2011,32(1):28-37.
[9] KALIKI S,SHIELDS C,SHIELDS J.Uveal melanoma:estimating prognosis[J].Int Ophthalmol,2015,63(2):93-102.
[10] KRANTZ B A,DAVE N,KOMATSUBARA K M,MARR B P,CARVAJAL R D.Uveal melanoma:epidemiology,etiology,and treatment of primary disease[J].Clin Ophthalmol,2017,11:279-289.
[11] LOGAN P,BURNIER J,BURNIER M N.Vascular endothelial growth factor expression and inhibition in uveal melanoma cell lines[J].Ecancermedicalscience,2013,7:336.
[12] FRANCIS J H,KIM J,LIN A,FOLBERG R,IYER S,ABRAMSON D H.Growth of Uveal melanoma following intravitreal bevacizumab[J].Ocul Oncol Pathol,2017,3(2):117-121.
[13] GE H,LUO H.Overview of advances in vasculogenic mimicry- a potential target for tumor therapy[J].Cancer Manag Res,2018,10:2429-2437.
[14] TRIOZZI P L,SINGH A D.Adjuvant therapy of uveal melanoma:current status[J].Ocul Oncol Pathol,2015,1:54-62.
[15] TARLAN B,KIRATLI H.Uveal melanoma:current trends in diagnosis and management[J].Turkish Ophthalmol,2016,46(3):123-137.
[16] Clinical Trials.gov.[EB/OL].[2018-05-01].http://www.clinicaltrials.gov.
[17] PEREIRA P R,ODASHIRO A N,LIM L A,MIYAMOTO C,BLANCO P L,ODASHIRO M,et al.Current and emerging treatment options for uveal melanoma[J].Clin Ophthalmol,2013,7:1669-1682.
[18] RODRGUEZ A,DUEAS-GONZALEZ A,DELGADO-PELAYO S.Clinical presentation and management of uveal melanoma[J].Mol Clin Oncol,2016,5(6),675-677.
[19] YANG J,MANSON D K,MARR B P,CARVAJAL R D.Treatment of uveal melanoma:where are we now[J]?Ther Adv Med Oncol,2018,10:1758834018757175.
[20] PAPASTEFANOU V P,COHEN V M.Uveal melanoma[J].J Skin Cancer,2011,2011:573974.
[21] OLIVA M,RULLAN A J,PIULATS J M.Uveal melanoma as a target for immune-therapy[J].Ann Tran Med,2016,4(9):172.
[22] FENG X,DEGESE M S,IGLESIAS-BARTOLOME R,VAQUE J P,MOLINOLO A A,RODRIGUES M,et al.Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a Trio-regulated Rho GTPase signaling circuitry[J].Cancer Cell,2014,25(6):831-845.
[23] AVRIL M F,AAMDAL S,GROB J J,HAUSCHILD A,MOHR P,BONERANDI J J,et al.Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma.A phase Ⅲ study[J].Clin Oncol,2004,22(6):1118-1125.
[24] ZIMMER L,VAUBEL J,MOHR P,HAUSCHILD A,UTIKAL J,SIMON J,et al.Phase II DeCOG-study of Ipilimumab in pretreated and treatment-nave patients with metastatic uveal melanoma[J].PLoS One,2015,10(3):e0118564.
[25] SURRIGA O,RAJASEKHAR V K,AMBROSINI G,DOGAN Y,HUANG R,SCHWARTZ G K,et al.A c-Met inhibitor prevents metastasis in a metastatic uveal melanoma model[J].Mol Cancer Ther,2013,12(12):2817-2826.
[26] HU Z,MCMICHAEL E,CAMPBELL A,LONDON A C,CARSON E W.Tissue factor-targeted immunotherapy of melanoma and triple negative breast cancer using a second-generation ICON[J].Imm Cancer,2015,3(Suppl 2):P304.
[27] LEYVRAZ S,PIPERNO-NEUMANN S,SUCIU S,BAURAIN J F,ZDZIENICKI M,TESTORI A,et al.Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021):A multicentric randomized trial[J].Ann Oncol,2014,25(3):742-746.
[28] BARAK V,FRENKEL S,KALICKMAN I,MANIOTIS A J,FOLBERG R,PEER J.Serum markers to detect metastatic uveal melanoma[J].In Ant Res,2007,27(4A):1897-1900.
[29] COOLS-LARTIGUE J J,MCCAULEY C S,MARSHALL J C A,CESARE S D I,GREGOIRE F,ANTECKA E,et al.Immunomagnetic isolation and in vitro expansion of human uveal melanoma cell lines[J].Mol Vis,2008,14:50-55.
[30] HERCEG Z,HAINAUT P.Genetic and epigenetic alterations as biomarkers for cancer detection,diagnosis and prognosis[J].Mol Oncol,2007,1(1):26-41.

相似文献/References:

[1]周朋义 彭广华.视网膜色素变性治疗的研究进展[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2012,32(5):.
[2]杨红 阴正勤.眼球震颤的诊断与治疗研究进展[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2012,32(5):.
[3]邵毅 周琼 易昀敏 余瑶 裴重刚 吴晓蓉 梅峰 占敏艳.鬼针草叶治疗非增生型糖尿病视网膜病变的临床研究[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2013,33(6):.
[4]杨世琳 杜改萍 郝玉华.频域OCT观察Vogt-小柳-原田病患者病程中黄斑中心凹的图像特点[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2013,33(6):.
[5]曾春梅 文勇 成旋.特发性息肉样脉络膜血管病变的治疗进展[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2013,33(7):.
[6]蒋永强 吴晓梅.眼睑皮脂腺癌治疗的研究进展[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2008,28(9):.
[7]李明 张永喜 王胜根.葡萄膜黑色素瘤术后自体细胞因子诱导的杀伤细胞治疗效果观察[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2012,32(8):.
[8]王玲 郑振优 邢健强.白内障摘出联合人工晶状体植入术治疗闭角型青光眼合并白内障临床疗效分析[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2012,32(9):.
[9]毛新帮 游志鹏 赵菊莲.应用25G经结膜无缝合玻璃体切割系统治疗特发性黄斑前膜[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2013,33(3):.
[10]刘鑫 苏冠方 王晨光 祝伟.玻璃体切割联合眼内填充术后眼压升高的相关因素分析及治疗[J].开元棋牌电脑_开元棋牌一直在维护_开元棋牌怎么对刷,2013,33(11):.

备注/Memo

备注/Memo:
更新日期/Last Update: 2019-04-15